BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35072253)

  • 1. Metformin in selected malignancies in women.
    Markowska A; Stanislawiak-Rudowicz J; Kasprzak T; Markowska J; Szarszewska M
    Ginekol Pol; 2022; 93(5):416-421. PubMed ID: 35072253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy.
    Karadeniz Z; Aynacıoğlu AŞ; Bilir A; Tuna MY
    Med Hypotheses; 2020 Jan; 134():109420. PubMed ID: 31634770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular action of insulin-sensitizing agents].
    Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
    Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives of metformin use in endometrial cancer and other gynaecological malignancies.
    Barczyński B; Frąszczak K; Kotarski J
    J Drug Target; 2022 Apr; 30(4):359-367. PubMed ID: 34753372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.
    Rozengurt E; Sinnett-Smith J; Kisfalvi K
    Clin Cancer Res; 2010 May; 16(9):2505-11. PubMed ID: 20388847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer.
    Cai D; Sun H; Qi Y; Zhao X; Feng M; Wu X
    Int J Gynecol Cancer; 2016 Nov; 26(9):1667-1672. PubMed ID: 27654259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning.
    Gadducci A; Biglia N; Tana R; Cosio S; Gallo M
    Crit Rev Oncol Hematol; 2016 Sep; 105():73-83. PubMed ID: 27378194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targets of metformin antitumor action.
    Sośnicki S; Kapral M; Węglarz L
    Pharmacol Rep; 2016 Oct; 68(5):918-25. PubMed ID: 27362768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications.
    Sivalingam VN; Myers J; Nicholas S; Balen AH; Crosbie EJ
    Hum Reprod Update; 2014; 20(6):853-68. PubMed ID: 25013215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.
    Xie Y; Wang YL; Yu L; Hu Q; Ji L; Zhang Y; Liao QP
    J Steroid Biochem Mol Biol; 2011 Sep; 126(3-5):113-20. PubMed ID: 21168492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin: taking away the candy for cancer?
    Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
    Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin and Breast Cancer: Molecular Targets.
    Faria J; Negalha G; Azevedo A; Martel F
    J Mammary Gland Biol Neoplasia; 2019 Jun; 24(2):111-123. PubMed ID: 30903363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin in cancer.
    Mallik R; Chowdhury TA
    Diabetes Res Clin Pract; 2018 Sep; 143():409-419. PubMed ID: 29807101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism.
    Takiyama Y; Harumi T; Watanabe J; Fujita Y; Honjo J; Shimizu N; Makino Y; Haneda M
    Diabetes; 2011 Mar; 60(3):981-92. PubMed ID: 21282369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metformin, an antidiabetic molecule with anti-cancer properties].
    Beck E; Scheen AJ
    Rev Med Liege; 2013 Sep; 68(9):444-9. PubMed ID: 24180199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line.
    Lange C; Machado Weber A; Schmidt R; Schroeder C; Strowitzki T; Germeyer A
    PLoS One; 2021; 16(3):e0248103. PubMed ID: 33690729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines.
    Laskov I; Abou-Nader P; Amin O; Philip CA; Beauchamp MC; Yasmeen A; Gotlieb WH
    Int J Gynecol Cancer; 2016 Sep; 26(7):1213-21. PubMed ID: 27643646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin.
    Sivalingam VN; Latif A; Kitson S; McVey R; Finegan KG; Marshall K; Lisanti MP; Sotgia F; Stratford IJ; Crosbie EJ
    Br J Cancer; 2020 Jan; 122(1):62-71. PubMed ID: 31819173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.